Charles Schwab Investment Management Inc. lifted its holdings in Insmed Incorporated (NASDAQ:INSM) by 10.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 490,072 shares of the biopharmaceutical company’s stock after acquiring an additional 47,353 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.55% of Insmed worth $12,546,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Federated Investors Inc. PA purchased a new stake in Insmed during the first quarter worth $9,825,000. Carillon Tower Advisers Inc. purchased a new position in Insmed during the second quarter valued at $26,785,000. Asymmetry Capital Management L.P. lifted its holdings in Insmed by 371.6% during the second quarter. Asymmetry Capital Management L.P. now owns 730,440 shares of the biopharmaceutical company’s stock valued at $18,699,000 after purchasing an additional 575,553 shares in the last quarter. Swiss National Bank lifted its holdings in Insmed by 9.7% during the second quarter. Swiss National Bank now owns 154,100 shares of the biopharmaceutical company’s stock valued at $3,945,000 after purchasing an additional 13,600 shares in the last quarter. Finally, Eagle Asset Management Inc. purchased a new position in Insmed during the second quarter valued at $38,439,000.
Shares of INSM traded up $1.28 during trading on Friday, reaching $17.40. 1,132,046 shares of the company traded hands, compared to its average volume of 1,249,000. The company has a quick ratio of 7.31, a current ratio of 7.54 and a debt-to-equity ratio of 1.01. The stock has a market cap of $1.55 billion, a PE ratio of -4.17 and a beta of 2.97. The stock has a 50-day simple moving average of $17.59 and a 200-day simple moving average of $23.41. Insmed Incorporated has a twelve month low of $11.31 and a twelve month high of $33.13.
Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $30.00 million during the quarter, compared to analyst estimates of $26.30 million. On average, equities research analysts predict that Insmed Incorporated will post -2.99 EPS for the current year.
Several equities analysts have issued reports on INSM shares. ValuEngine downgraded shares of Insmed from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Goldman Sachs Group assumed coverage on shares of Insmed in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $30.00 price target on the stock. Zacks Investment Research downgraded shares of Insmed from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Credit Suisse Group reissued a “buy” rating and issued a $40.00 price target on shares of Insmed in a research note on Tuesday, September 10th. Finally, BidaskClub downgraded shares of Insmed from a “sell” rating to a “strong sell” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $35.71.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Story: Market Timing – The Benefits and the Danger
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.